Product Details:
Minimum Order Quantity | 100 Vial |
Brand | CIZUMAB 400 MG |
Manufacturer | Hetero |
Packaging | Vial |
Dosage Form | Injection |
Storage | 2* |
CIZUMAB 400 MG Bevacizumab, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations (see